Josh Enomoto

Josh Enomoto

InvestorPlace Contributor

Brokering multi-million-dollar deals with some of the world’s biggest companies and providing in-depth marketing analyses, Josh Enomoto takes his firsthand knowledge of the corporate boardroom and delivers them across several media outlets. In addition to his work at InvestorPlace, Josh contributes content for Benzinga, TipRanks, EmergingGrowth and Blockster. He is also a guest expert at CGTN America.

While leaving no stone unturned regarding sector coverage, Josh has written extensively about cryptocurrencies. You can follow him on Blockster, a crypto-centric social media platform and on LinkedIn.

Recent Articles

Canopy Growth Is Intriguing If You Can Get Over the Credibility Issue

By Josh Enomoto, InvestorPlace Contributor

After so many misses, Canopy Growth stock suffers from a credibility drain. Nevertheless, political and medicinal shifts present an interesting contrarian case for CGC.

The Good, Bad, and Ugly for Energy Transfer

By Josh Enomoto, InvestorPlace Contributor

A few weeks was all it took to deflate the comeback narrative for ET stock. Here are the factors that could play a big role in where Energy Transfer goes from here.

How the U.S. Constitution Is Helping Inovio Pharmaceuticals

By Josh Enomoto, InvestorPlace Contributor

INO stock has transformed this year from unknown to a Wall Street darling. But with a worsening pandemic, the long-term case for Inovio has become even more credible.

Bank of America Is a Q2 Earnings Story to Avoid

By Josh Enomoto, InvestorPlace Contributor

Just a few days ago, optimism reigned for BAC stock on positive coronavirus news. But now, that narrative has changed for the worse.

Royal Caribbean May See a Quick Lift Off Positive Industry News

By Josh Enomoto, InvestorPlace Contributor

In the near term, positive industry news bodes well for RCL stock. But if you have a longer-term horizon, I wouldn’t be too quick to book a trip with Royal Caribbean.

An Anxious Q2 Earnings Test Awaits Citigroup

By Josh Enomoto, InvestorPlace Contributor

A disconnect between ugly coronavirus headlines and surprisingly strong business sentiment sets up a possible bullish trade for C stock. But you better punch out quickly because the longer-term narrative is very risky.

Whiting Petroleum Is Unanchored from Reality

By Josh Enomoto, InvestorPlace Contributor

Without question, most investors should avoid even thinking about WLL stock. It’s not so much that it’s a discount-bin investment but rather, why it is that makes it so treacherous.

3 Reasons to Invest in, Not Trade iBio

By Josh Enomoto, InvestorPlace Contributor

During the initial strike of the novel coronavirus, IBIO stock was a huge gamble. But with the stakes raised, the underlying biotech firm could turn out to be instrumental.

Here’s the Crazy Math Supporting Marathon Oil

By Josh Enomoto, InvestorPlace Contributor

Conservative investors should steer clear of the oil industry. But if you can tolerate extreme volatility, MRO stock may turn out to be a surprising contrarian idea.

XpresSpa Is Bold, but Can It Be Profitable?

By Josh Enomoto, InvestorPlace Contributor

XpresSpa deserves all the credit in the world for attacking the coronavirus head on. But that alone won’t maintain momentum for XSPA stock.

Load More